Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier

4 Aug 2023

Abstract excerpt

Background Molnupiravir is an orally bioavailable prodrug of the nucleoside analogue β-D-N4-hydroxycytidine (NHC) and is used to treat coronavirus disease 2019 (COVID-19). However, the pharmacokinetics and transplacental transfer of molnupiravir in pregnant women are still not well understood. In the present study, we investigated the hypothesis that molnupiravir and NHC cross the blood-placenta barrier into the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to COVID-19 Impact on Reproduction
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37544201
DOI: 10.1016/j.ebiom.2023.104748

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrierPMID 37544201Read ↗

Mechanisms of drug transfer across the human placenta.Semantic proximity Read ↗

Drug Interactions at the Human Placenta: What is the Evidence?Semantic proximity Read ↗

Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion ExperimentsSemantic proximity Read ↗

Overview of Drug Transporters in Human PlacentaSemantic proximity Read ↗

Drug Transport Across the PlacentaSemantic proximity Read ↗

Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the <em>ex vivo</em> Human Placental Perfusion ModelSemantic proximity Read ↗

Drug Transporters Expressed in the Human Placenta and Models for Studying Maternal‐Fetal Drug TransferSemantic proximity Read ↗

Placental Transfer of Maraviroc in an Ex Vivo Human Cotyledon Perfusion Model and Influence of ABC Transporter ExpressionSemantic proximity Read ↗

Mechanisms of altered hepatic drug disposition during pregnancy: small moleculesSemantic proximity Read ↗

Call to Action: Harmonisation of Pharmacovigilance Regulations for Post-marketing Pregnancy and Breastfeeding Safety StudiesSemantic proximity Read ↗

Maternally administered naltrexone and its major active metabolite 6β-naltrexol transport across the placental barrier <i>in vitro</i>Semantic proximity Read ↗

Mechanisms regulating toxicant disposition to the embryo during early pregnancy: An interspecies comparisonSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.